Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hepatoblastoma | 26 | 2025 | 179 | 5.710 |
Why?
|
Liver Neoplasms | 36 | 2025 | 1318 | 5.050 |
Why?
|
Oncogene Proteins, Fusion | 28 | 2025 | 213 | 3.570 |
Why?
|
Carcinoma, Hepatocellular | 15 | 2025 | 933 | 2.620 |
Why?
|
Translocation, Genetic | 21 | 2025 | 360 | 2.220 |
Why?
|
Dermatofibrosarcoma | 9 | 2018 | 17 | 2.210 |
Why?
|
Gene Rearrangement | 15 | 2014 | 322 | 2.160 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 23 | 2015 | 1296 | 1.860 |
Why?
|
Biomarkers, Tumor | 22 | 2024 | 1526 | 1.840 |
Why?
|
In Situ Hybridization, Fluorescence | 28 | 2016 | 768 | 1.830 |
Why?
|
Soft Tissue Neoplasms | 9 | 2014 | 121 | 1.820 |
Why?
|
Gene Fusion | 6 | 2024 | 57 | 1.680 |
Why?
|
Skin Neoplasms | 10 | 2020 | 862 | 1.270 |
Why?
|
Child | 73 | 2025 | 24559 | 1.190 |
Why?
|
Calmodulin-Binding Proteins | 6 | 2014 | 63 | 1.180 |
Why?
|
Immunohistochemistry | 22 | 2017 | 1706 | 1.070 |
Why?
|
Sarcoma, Ewing | 7 | 2013 | 110 | 1.050 |
Why?
|
Neoplasms | 8 | 2025 | 2803 | 0.990 |
Why?
|
beta Catenin | 7 | 2022 | 207 | 0.980 |
Why?
|
Adenomatous Polyposis Coli | 2 | 2018 | 42 | 0.960 |
Why?
|
Humans | 139 | 2025 | 125667 | 0.950 |
Why?
|
RNA-Binding Proteins | 8 | 2014 | 576 | 0.940 |
Why?
|
Transcription Factors | 15 | 2022 | 2604 | 0.920 |
Why?
|
Laboratory Proficiency Testing | 1 | 2024 | 8 | 0.900 |
Why?
|
Neoplastic Syndromes, Hereditary | 1 | 2025 | 73 | 0.890 |
Why?
|
Mutation | 13 | 2022 | 5893 | 0.880 |
Why?
|
Sarcoma, Clear Cell | 3 | 2009 | 20 | 0.860 |
Why?
|
Neoplasm Proteins | 7 | 2019 | 676 | 0.860 |
Why?
|
High-Throughput Nucleotide Sequencing | 6 | 2024 | 883 | 0.810 |
Why?
|
Adolescent | 45 | 2024 | 19441 | 0.790 |
Why?
|
Child, Preschool | 34 | 2025 | 14106 | 0.770 |
Why?
|
Liposarcoma, Myxoid | 2 | 2011 | 3 | 0.730 |
Why?
|
Male | 75 | 2024 | 61776 | 0.720 |
Why?
|
Bone Neoplasms | 7 | 2018 | 427 | 0.720 |
Why?
|
Female | 79 | 2024 | 66998 | 0.710 |
Why?
|
Neoplasm Transplantation | 4 | 2017 | 383 | 0.700 |
Why?
|
Proto-Oncogene Proteins | 7 | 2023 | 554 | 0.690 |
Why?
|
Sarcoma | 5 | 2014 | 182 | 0.690 |
Why?
|
Trans-Activators | 4 | 2015 | 800 | 0.680 |
Why?
|
Repressor Proteins | 6 | 2025 | 817 | 0.680 |
Why?
|
Genetic Predisposition to Disease | 6 | 2025 | 3174 | 0.670 |
Why?
|
Neovascularization, Pathologic | 3 | 2017 | 241 | 0.670 |
Why?
|
Carcinoma, Mucoepidermoid | 2 | 2015 | 13 | 0.650 |
Why?
|
Oncogene Fusion | 4 | 2017 | 22 | 0.620 |
Why?
|
Biopsy | 8 | 2021 | 1241 | 0.620 |
Why?
|
Infant | 30 | 2025 | 12572 | 0.620 |
Why?
|
DNA, Neoplasm | 10 | 2020 | 306 | 0.610 |
Why?
|
Neoplasms, Second Primary | 2 | 2017 | 152 | 0.600 |
Why?
|
Proto-Oncogene Proteins B-raf | 2 | 2017 | 193 | 0.590 |
Why?
|
Fibrosarcoma | 3 | 2012 | 26 | 0.580 |
Why?
|
Molecular Diagnostic Techniques | 3 | 2022 | 152 | 0.580 |
Why?
|
Liver Neoplasms, Experimental | 1 | 2017 | 59 | 0.570 |
Why?
|
Young Adult | 22 | 2021 | 9093 | 0.570 |
Why?
|
MAP Kinase Signaling System | 2 | 2019 | 316 | 0.570 |
Why?
|
Genetic Testing | 5 | 2024 | 1013 | 0.560 |
Why?
|
Fibromatosis, Aggressive | 3 | 2012 | 8 | 0.560 |
Why?
|
Thyroid Neoplasms | 2 | 2020 | 189 | 0.560 |
Why?
|
Chromosomes, Human, Pair 1 | 1 | 2017 | 140 | 0.550 |
Why?
|
Adult | 46 | 2022 | 29734 | 0.540 |
Why?
|
Chromosomes, Human, Pair 6 | 1 | 2017 | 143 | 0.540 |
Why?
|
Genes, APC | 2 | 2018 | 13 | 0.540 |
Why?
|
Chromosomes, Human, Pair 7 | 2 | 2019 | 74 | 0.540 |
Why?
|
Thrombocytosis | 1 | 2017 | 34 | 0.540 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2017 | 97 | 0.530 |
Why?
|
Phenotype | 5 | 2017 | 4273 | 0.530 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 7 | 2021 | 1256 | 0.530 |
Why?
|
Chromosomes, Human, Pair 12 | 2 | 2016 | 92 | 0.520 |
Why?
|
Cholangiocarcinoma | 1 | 2017 | 107 | 0.520 |
Why?
|
Liver | 6 | 2023 | 1749 | 0.520 |
Why?
|
RNA-Binding Protein EWS | 10 | 2014 | 33 | 0.510 |
Why?
|
Zinc Finger Protein GLI1 | 1 | 2016 | 35 | 0.510 |
Why?
|
Epithelioid Cells | 3 | 2012 | 11 | 0.500 |
Why?
|
Liver Diseases | 2 | 2019 | 368 | 0.500 |
Why?
|
Calcium-Binding Proteins | 2 | 2015 | 326 | 0.500 |
Why?
|
Gene Expression Regulation, Neoplastic | 13 | 2022 | 1962 | 0.500 |
Why?
|
Oncogenes | 1 | 2016 | 174 | 0.500 |
Why?
|
Chromosomes, Human, Pair 17 | 4 | 2014 | 370 | 0.490 |
Why?
|
RNA-Binding Protein FUS | 2 | 2012 | 13 | 0.490 |
Why?
|
Thyroid Nodule | 1 | 2015 | 19 | 0.490 |
Why?
|
Neuroblastoma | 2 | 2017 | 528 | 0.480 |
Why?
|
Salivary Gland Neoplasms | 2 | 2015 | 55 | 0.480 |
Why?
|
Hemangioendothelioma, Epithelioid | 1 | 2015 | 10 | 0.480 |
Why?
|
Mental Retardation, X-Linked | 1 | 2015 | 71 | 0.470 |
Why?
|
Cauda Equina | 1 | 2014 | 9 | 0.470 |
Why?
|
Carcinogenesis | 2 | 2023 | 340 | 0.470 |
Why?
|
Peripheral Nervous System Neoplasms | 1 | 2014 | 12 | 0.470 |
Why?
|
Cyclin B | 1 | 2014 | 22 | 0.460 |
Why?
|
Neoplasm Recurrence, Local | 8 | 2024 | 1160 | 0.460 |
Why?
|
Glomus Tumor | 1 | 2014 | 13 | 0.460 |
Why?
|
WT1 Proteins | 1 | 2014 | 27 | 0.460 |
Why?
|
Prognosis | 13 | 2021 | 4690 | 0.460 |
Why?
|
Cell Line, Tumor | 8 | 2024 | 3396 | 0.450 |
Why?
|
Proto-Oncogene Proteins c-sis | 2 | 2012 | 19 | 0.440 |
Why?
|
Histiocytosis, Langerhans-Cell | 1 | 2017 | 221 | 0.440 |
Why?
|
Sarcoma, Synovial | 4 | 2021 | 21 | 0.430 |
Why?
|
Actins | 1 | 2016 | 346 | 0.430 |
Why?
|
Intracellular Signaling Peptides and Proteins | 3 | 2015 | 558 | 0.420 |
Why?
|
Collagen Type I | 2 | 2012 | 112 | 0.420 |
Why?
|
Pathologists | 2 | 2024 | 29 | 0.420 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 2 | 2013 | 66 | 0.420 |
Why?
|
Chromosomes, Human, Pair 11 | 4 | 2013 | 87 | 0.420 |
Why?
|
Lymphoma, Large-Cell, Anaplastic | 3 | 2022 | 46 | 0.420 |
Why?
|
Neuroectodermal Tumors, Primitive, Peripheral | 3 | 2008 | 14 | 0.410 |
Why?
|
Carcinoma | 1 | 2015 | 290 | 0.410 |
Why?
|
Methyl-CpG-Binding Protein 2 | 1 | 2015 | 310 | 0.410 |
Why?
|
Hodgkin Disease | 2 | 2015 | 292 | 0.400 |
Why?
|
Neoplastic Cells, Circulating | 2 | 2024 | 74 | 0.400 |
Why?
|
Receptor Protein-Tyrosine Kinases | 3 | 2022 | 130 | 0.400 |
Why?
|
Thoracic Neoplasms | 1 | 2012 | 38 | 0.400 |
Why?
|
DNA-Binding Proteins | 4 | 2011 | 2054 | 0.400 |
Why?
|
Leukemia, Myeloid, Acute | 2 | 2017 | 538 | 0.400 |
Why?
|
Myeloproliferative Disorders | 2 | 2013 | 87 | 0.400 |
Why?
|
Thoracic Vertebrae | 1 | 2012 | 68 | 0.390 |
Why?
|
Rhabdomyosarcoma, Alveolar | 2 | 2009 | 36 | 0.390 |
Why?
|
Isochromosomes | 1 | 2012 | 18 | 0.390 |
Why?
|
Spinal Neoplasms | 1 | 2012 | 58 | 0.390 |
Why?
|
Cell Differentiation | 4 | 2021 | 1912 | 0.390 |
Why?
|
Chromosome Aberrations | 6 | 2020 | 620 | 0.380 |
Why?
|
Parotid Gland | 1 | 2011 | 20 | 0.380 |
Why?
|
Chromosomes, Human, Pair 8 | 2 | 2024 | 79 | 0.380 |
Why?
|
Middle Aged | 34 | 2024 | 27000 | 0.370 |
Why?
|
Vulvar Neoplasms | 2 | 2008 | 18 | 0.370 |
Why?
|
Stem Cells | 1 | 2016 | 711 | 0.370 |
Why?
|
Xenograft Model Antitumor Assays | 5 | 2024 | 908 | 0.370 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 2 | 2024 | 144 | 0.370 |
Why?
|
Cell Dedifferentiation | 1 | 2010 | 21 | 0.350 |
Why?
|
Liposarcoma | 1 | 2010 | 22 | 0.350 |
Why?
|
Simian virus 40 | 3 | 2008 | 199 | 0.350 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2010 | 96 | 0.350 |
Why?
|
DNA Primers | 2 | 2010 | 658 | 0.350 |
Why?
|
Stomach Neoplasms | 2 | 2016 | 548 | 0.340 |
Why?
|
Chromosome Breakpoints | 1 | 2010 | 81 | 0.340 |
Why?
|
Histiocytoma, Benign Fibrous | 1 | 2010 | 12 | 0.340 |
Why?
|
Polyomavirus Infections | 2 | 2008 | 90 | 0.340 |
Why?
|
Chimera | 1 | 2010 | 83 | 0.340 |
Why?
|
Tumor Virus Infections | 2 | 2008 | 135 | 0.340 |
Why?
|
Sequence Analysis, RNA | 2 | 2024 | 372 | 0.330 |
Why?
|
Neoplasm Invasiveness | 4 | 2017 | 623 | 0.330 |
Why?
|
SMARCB1 Protein | 2 | 2020 | 38 | 0.320 |
Why?
|
Receptors, Cell Surface | 1 | 2011 | 475 | 0.320 |
Why?
|
DNA Mutational Analysis | 6 | 2015 | 800 | 0.320 |
Why?
|
Treatment Outcome | 13 | 2023 | 12420 | 0.320 |
Why?
|
Pathology | 1 | 2009 | 41 | 0.320 |
Why?
|
CREB-Binding Protein | 1 | 2009 | 64 | 0.320 |
Why?
|
Heterografts | 3 | 2024 | 176 | 0.310 |
Why?
|
Cell Transformation, Neoplastic | 2 | 2011 | 630 | 0.310 |
Why?
|
Antigens, CD34 | 4 | 2012 | 109 | 0.310 |
Why?
|
Mice | 14 | 2024 | 17727 | 0.310 |
Why?
|
Palatine Tonsil | 2 | 2008 | 36 | 0.310 |
Why?
|
Wnt Proteins | 2 | 2009 | 211 | 0.300 |
Why?
|
Neoplasm Staging | 6 | 2021 | 1278 | 0.300 |
Why?
|
Chondrosarcoma | 1 | 2008 | 11 | 0.300 |
Why?
|
Aged | 20 | 2018 | 19900 | 0.300 |
Why?
|
Pharyngeal Diseases | 1 | 2008 | 19 | 0.300 |
Why?
|
Cerebellar Neoplasms | 1 | 2012 | 392 | 0.290 |
Why?
|
Genomics | 5 | 2024 | 1516 | 0.290 |
Why?
|
Medulloblastoma | 1 | 2012 | 477 | 0.280 |
Why?
|
Myofibroma | 2 | 2017 | 9 | 0.280 |
Why?
|
Glioma | 2 | 2022 | 513 | 0.270 |
Why?
|
Fasciitis | 2 | 2017 | 19 | 0.270 |
Why?
|
Infant, Newborn | 12 | 2024 | 8249 | 0.270 |
Why?
|
Algorithms | 2 | 2022 | 1632 | 0.270 |
Why?
|
Tumor Suppressor Protein p53 | 5 | 2019 | 740 | 0.260 |
Why?
|
Real-Time Polymerase Chain Reaction | 4 | 2016 | 509 | 0.260 |
Why?
|
Combined Modality Therapy | 5 | 2021 | 1248 | 0.260 |
Why?
|
Immunophenotyping | 3 | 2017 | 329 | 0.260 |
Why?
|
Sarcoma, Alveolar Soft Part | 3 | 2012 | 10 | 0.250 |
Why?
|
Sequence Analysis, DNA | 6 | 2022 | 1759 | 0.250 |
Why?
|
Animals | 16 | 2024 | 34349 | 0.250 |
Why?
|
Intestinal Neoplasms | 1 | 2006 | 40 | 0.250 |
Why?
|
Tumor Burden | 2 | 2017 | 230 | 0.240 |
Why?
|
Risk Factors | 9 | 2025 | 10340 | 0.240 |
Why?
|
Karyotyping | 6 | 2016 | 324 | 0.240 |
Why?
|
Diagnosis, Differential | 7 | 2024 | 1901 | 0.240 |
Why?
|
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 4 | 2015 | 177 | 0.240 |
Why?
|
Peutz-Jeghers Syndrome | 1 | 2025 | 27 | 0.240 |
Why?
|
Fatal Outcome | 5 | 2017 | 359 | 0.230 |
Why?
|
Base Sequence | 9 | 2012 | 3108 | 0.230 |
Why?
|
Carcinoma, Renal Cell | 2 | 2020 | 241 | 0.230 |
Why?
|
Core Binding Factor Alpha 2 Subunit | 1 | 2025 | 39 | 0.230 |
Why?
|
Li-Fraumeni Syndrome | 1 | 2025 | 46 | 0.230 |
Why?
|
Germ-Line Mutation | 3 | 2018 | 342 | 0.230 |
Why?
|
Databases, Factual | 3 | 2020 | 1186 | 0.230 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 2 | 2024 | 173 | 0.230 |
Why?
|
Proto-Oncogene Proteins c-ets | 1 | 2025 | 58 | 0.230 |
Why?
|
Glypicans | 1 | 2024 | 39 | 0.230 |
Why?
|
Histiocytes | 2 | 2017 | 23 | 0.230 |
Why?
|
Molecular Sequence Data | 9 | 2012 | 3896 | 0.220 |
Why?
|
Interleukin-15 | 1 | 2024 | 93 | 0.220 |
Why?
|
Chromosomes, Human, Pair 22 | 6 | 2013 | 103 | 0.220 |
Why?
|
Indocyanine Green | 1 | 2024 | 55 | 0.220 |
Why?
|
Molecular Biology | 2 | 2011 | 80 | 0.220 |
Why?
|
Sensitivity and Specificity | 2 | 2024 | 2060 | 0.210 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2025 | 128 | 0.210 |
Why?
|
Mice, SCID | 2 | 2017 | 583 | 0.210 |
Why?
|
Disease-Free Survival | 5 | 2020 | 907 | 0.210 |
Why?
|
Leukemia, Megakaryoblastic, Acute | 1 | 2022 | 19 | 0.200 |
Why?
|
Rare Diseases | 1 | 2024 | 190 | 0.200 |
Why?
|
Burkitt Lymphoma | 1 | 2024 | 144 | 0.200 |
Why?
|
alpha-Fetoproteins | 3 | 2023 | 131 | 0.200 |
Why?
|
Sclerosis | 2 | 2012 | 34 | 0.200 |
Why?
|
Cytogenetic Analysis | 3 | 2014 | 81 | 0.200 |
Why?
|
Neoplasm Grading | 2 | 2014 | 278 | 0.200 |
Why?
|
Antigens, Polyomavirus Transforming | 3 | 2008 | 88 | 0.190 |
Why?
|
Neutrophils | 2 | 2001 | 381 | 0.190 |
Why?
|
Yttrium Radioisotopes | 1 | 2021 | 18 | 0.190 |
Why?
|
Ki-67 Antigen | 3 | 2024 | 114 | 0.190 |
Why?
|
Retrospective Studies | 11 | 2023 | 16417 | 0.190 |
Why?
|
Skull Neoplasms | 1 | 2001 | 14 | 0.190 |
Why?
|
Ki-1 Antigen | 1 | 2001 | 28 | 0.180 |
Why?
|
Lymphatic Metastasis | 3 | 2020 | 418 | 0.180 |
Why?
|
Tumor Cells, Cultured | 5 | 2020 | 1072 | 0.180 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2025 | 783 | 0.180 |
Why?
|
Osteosarcoma | 3 | 2003 | 255 | 0.180 |
Why?
|
Fixatives | 2 | 2012 | 14 | 0.180 |
Why?
|
Disease Models, Animal | 4 | 2023 | 4409 | 0.180 |
Why?
|
Paraffin Embedding | 2 | 2012 | 34 | 0.180 |
Why?
|
Formaldehyde | 2 | 2012 | 36 | 0.180 |
Why?
|
Epstein-Barr Virus Infections | 2 | 2022 | 294 | 0.170 |
Why?
|
Ubiquitin Thiolesterase | 2 | 2017 | 61 | 0.170 |
Why?
|
Hospitals | 1 | 2023 | 398 | 0.170 |
Why?
|
Carcinoma, Medullary | 1 | 2020 | 15 | 0.170 |
Why?
|
Bone Marrow | 3 | 2017 | 325 | 0.170 |
Why?
|
Hemangioma, Capillary | 1 | 2020 | 17 | 0.170 |
Why?
|
Cell Cycle Proteins | 3 | 2023 | 659 | 0.170 |
Why?
|
Carcinoma, Papillary | 1 | 2020 | 71 | 0.170 |
Why?
|
Sarcoma, Myeloid | 1 | 2019 | 12 | 0.160 |
Why?
|
Craniocerebral Trauma | 1 | 2001 | 139 | 0.160 |
Why?
|
Exome | 1 | 2024 | 1035 | 0.160 |
Why?
|
Proton Therapy | 1 | 2021 | 125 | 0.160 |
Why?
|
DNA Copy Number Variations | 2 | 2022 | 959 | 0.160 |
Why?
|
Leukocytosis | 2 | 2017 | 46 | 0.160 |
Why?
|
Precursor Cells, B-Lymphoid | 1 | 2019 | 15 | 0.160 |
Why?
|
Leukemia, Myelomonocytic, Juvenile | 1 | 2019 | 9 | 0.160 |
Why?
|
Ependymoma | 1 | 2021 | 164 | 0.160 |
Why?
|
Neoadjuvant Therapy | 1 | 2021 | 343 | 0.160 |
Why?
|
Central Nervous System Neoplasms | 1 | 2022 | 204 | 0.160 |
Why?
|
Azacitidine | 1 | 2019 | 53 | 0.160 |
Why?
|
Tracheal Neoplasms | 1 | 1999 | 20 | 0.160 |
Why?
|
Neuroectodermal Tumors, Primitive | 2 | 1998 | 55 | 0.160 |
Why?
|
Neuroectodermal Tumors | 1 | 1999 | 13 | 0.160 |
Why?
|
Embolization, Therapeutic | 1 | 2021 | 223 | 0.160 |
Why?
|
Lymph Nodes | 3 | 2017 | 379 | 0.160 |
Why?
|
Hemangioma | 1 | 2020 | 93 | 0.160 |
Why?
|
Serine Endopeptidases | 2 | 2018 | 181 | 0.150 |
Why?
|
Discoidin Domain Receptor 2 | 1 | 2018 | 5 | 0.150 |
Why?
|
Adamantinoma | 1 | 2018 | 2 | 0.150 |
Why?
|
Survival Rate | 4 | 2021 | 2073 | 0.150 |
Why?
|
Rhabdoid Tumor | 1 | 2019 | 50 | 0.150 |
Why?
|
Proteostasis | 1 | 2019 | 34 | 0.150 |
Why?
|
Postoperative Hemorrhage | 1 | 2019 | 84 | 0.150 |
Why?
|
Carcinoma, Small Cell | 1 | 2018 | 51 | 0.150 |
Why?
|
Non-alcoholic Fatty Liver Disease | 1 | 2023 | 398 | 0.150 |
Why?
|
Gene Amplification | 2 | 2013 | 234 | 0.150 |
Why?
|
Endoplasmic Reticulum Stress | 1 | 2019 | 121 | 0.150 |
Why?
|
Immunotherapy, Adoptive | 1 | 2024 | 832 | 0.150 |
Why?
|
DNA Replication | 1 | 2020 | 356 | 0.150 |
Why?
|
Biopsy, Fine-Needle | 4 | 2013 | 117 | 0.150 |
Why?
|
Promoter Regions, Genetic | 3 | 2017 | 1337 | 0.140 |
Why?
|
Cooperative Behavior | 2 | 2016 | 220 | 0.140 |
Why?
|
Hep G2 Cells | 1 | 2017 | 85 | 0.140 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2019 | 185 | 0.140 |
Why?
|
Chromosome Banding | 1 | 2017 | 138 | 0.140 |
Why?
|
Forkhead Transcription Factors | 3 | 2009 | 358 | 0.140 |
Why?
|
Follow-Up Studies | 5 | 2021 | 5195 | 0.140 |
Why?
|
Mice, Inbred NOD | 1 | 2017 | 299 | 0.140 |
Why?
|
Xanthogranuloma, Juvenile | 1 | 2017 | 31 | 0.140 |
Why?
|
Microtubule-Associated Proteins | 1 | 2018 | 246 | 0.140 |
Why?
|
Cell Nucleus | 3 | 2012 | 679 | 0.140 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 1 | 2017 | 111 | 0.130 |
Why?
|
Sarcoma, Small Cell | 1 | 1996 | 1 | 0.130 |
Why?
|
Cytogenetics | 1 | 1996 | 18 | 0.130 |
Why?
|
Monosomy | 1 | 1996 | 24 | 0.130 |
Why?
|
Hepatocyte Nuclear Factor 3-alpha | 1 | 2016 | 48 | 0.130 |
Why?
|
Tissue Array Analysis | 4 | 2009 | 138 | 0.130 |
Why?
|
Liver Transplantation | 3 | 2021 | 1039 | 0.130 |
Why?
|
Neoplasms, Glandular and Epithelial | 1 | 2016 | 39 | 0.130 |
Why?
|
Myelodysplastic Syndromes | 1 | 2017 | 139 | 0.130 |
Why?
|
Cohort Studies | 5 | 2024 | 4843 | 0.130 |
Why?
|
T-Lymphocytes | 1 | 2024 | 1727 | 0.130 |
Why?
|
Receptors, Purinergic P2X3 | 1 | 2015 | 3 | 0.130 |
Why?
|
Chromosome Mapping | 3 | 2023 | 1083 | 0.130 |
Why?
|
Transcriptional Regulator ERG | 2 | 2013 | 38 | 0.130 |
Why?
|
Nose Neoplasms | 1 | 1996 | 32 | 0.120 |
Why?
|
Proto-Oncogene Proteins c-ret | 1 | 2015 | 23 | 0.120 |
Why?
|
Transplantation Conditioning | 1 | 2017 | 325 | 0.120 |
Why?
|
NF-E2-Related Factor 2 | 1 | 2016 | 114 | 0.120 |
Why?
|
Kidney Neoplasms | 1 | 2020 | 440 | 0.120 |
Why?
|
Autophagy | 1 | 2019 | 393 | 0.120 |
Why?
|
Interleukin-8 | 1 | 2016 | 209 | 0.120 |
Why?
|
Genes, Tumor Suppressor | 1 | 2016 | 209 | 0.120 |
Why?
|
Ikaros Transcription Factor | 1 | 2015 | 28 | 0.120 |
Why?
|
Integrases | 1 | 2016 | 160 | 0.120 |
Why?
|
Ifosfamide | 1 | 2015 | 32 | 0.120 |
Why?
|
Mutagenesis | 1 | 2016 | 346 | 0.120 |
Why?
|
Vinblastine | 1 | 2015 | 53 | 0.120 |
Why?
|
Herpesvirus 4, Human | 4 | 2022 | 676 | 0.120 |
Why?
|
International Cooperation | 1 | 2015 | 158 | 0.120 |
Why?
|
Boronic Acids | 1 | 2015 | 46 | 0.120 |
Why?
|
Bortezomib | 1 | 2015 | 70 | 0.120 |
Why?
|
Mitotic Index | 1 | 2014 | 19 | 0.120 |
Why?
|
Recombination, Genetic | 1 | 2016 | 448 | 0.120 |
Why?
|
Pyrazines | 1 | 2015 | 73 | 0.120 |
Why?
|
Telomerase | 1 | 2015 | 168 | 0.110 |
Why?
|
Neoplasms, Multiple Primary | 3 | 2012 | 71 | 0.110 |
Why?
|
Ovarian Neoplasms | 1 | 2018 | 419 | 0.110 |
Why?
|
Adaptor Proteins, Signal Transducing | 2 | 2015 | 557 | 0.110 |
Why?
|
Diagnostic Errors | 1 | 2018 | 334 | 0.110 |
Why?
|
Mice, Knockout | 3 | 2019 | 3753 | 0.110 |
Why?
|
Risk | 1 | 2016 | 758 | 0.110 |
Why?
|
Myeloid Cells | 1 | 2014 | 102 | 0.110 |
Why?
|
Leukemia, Promyelocytic, Acute | 1 | 2014 | 24 | 0.110 |
Why?
|
Neoplasm Metastasis | 2 | 2020 | 702 | 0.110 |
Why?
|
Laparoscopy | 1 | 2019 | 493 | 0.110 |
Why?
|
Polymerase Chain Reaction | 5 | 2008 | 1590 | 0.110 |
Why?
|
Muir-Torre Syndrome | 1 | 2013 | 1 | 0.110 |
Why?
|
Long Interspersed Nucleotide Elements | 1 | 2013 | 32 | 0.110 |
Why?
|
Time Factors | 5 | 2021 | 6351 | 0.110 |
Why?
|
Retroperitoneal Neoplasms | 1 | 2013 | 30 | 0.100 |
Why?
|
Lymphoma, AIDS-Related | 2 | 2005 | 39 | 0.100 |
Why?
|
Chromosomal Instability | 1 | 2013 | 57 | 0.100 |
Why?
|
Lipoma | 1 | 2013 | 24 | 0.100 |
Why?
|
Phosphoproteins | 1 | 2015 | 420 | 0.100 |
Why?
|
Estrogen Receptor alpha | 1 | 2016 | 458 | 0.100 |
Why?
|
Fibroma | 1 | 2013 | 29 | 0.100 |
Why?
|
Multiplex Polymerase Chain Reaction | 1 | 2012 | 29 | 0.100 |
Why?
|
Cells, Cultured | 3 | 2017 | 3061 | 0.100 |
Why?
|
Mucin-4 | 1 | 2012 | 11 | 0.100 |
Why?
|
Brain Neoplasms | 1 | 2022 | 1297 | 0.100 |
Why?
|
Cell Lineage | 1 | 2014 | 355 | 0.100 |
Why?
|
Lymphocytes | 1 | 2014 | 410 | 0.100 |
Why?
|
Exons | 2 | 2012 | 800 | 0.100 |
Why?
|
Microsatellite Repeats | 1 | 2013 | 222 | 0.100 |
Why?
|
Forkhead Box Protein O1 | 2 | 2009 | 90 | 0.100 |
Why?
|
Mass Screening | 1 | 2018 | 787 | 0.100 |
Why?
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2013 | 84 | 0.100 |
Why?
|
Magnetic Resonance Imaging | 2 | 2014 | 3597 | 0.100 |
Why?
|
Atrophy | 1 | 2012 | 231 | 0.100 |
Why?
|
Age Factors | 2 | 2015 | 2831 | 0.100 |
Why?
|
Patched Receptors | 1 | 2011 | 31 | 0.100 |
Why?
|
Adenocarcinoma | 1 | 1999 | 1026 | 0.100 |
Why?
|
Tissue Fixation | 1 | 2012 | 38 | 0.100 |
Why?
|
Patched-1 Receptor | 1 | 2011 | 39 | 0.100 |
Why?
|
Genes, Neoplasm | 1 | 2012 | 80 | 0.090 |
Why?
|
Cross Reactions | 1 | 2012 | 192 | 0.090 |
Why?
|
Fibromatosis, Abdominal | 1 | 2011 | 1 | 0.090 |
Why?
|
Mouth Neoplasms | 1 | 2012 | 84 | 0.090 |
Why?
|
Alleles | 1 | 2016 | 1617 | 0.090 |
Why?
|
Primary Myelofibrosis | 1 | 2012 | 51 | 0.090 |
Why?
|
Hepatectomy | 2 | 2023 | 112 | 0.090 |
Why?
|
Proto-Oncogene Protein c-fli-1 | 3 | 2008 | 13 | 0.090 |
Why?
|
Hematopoietic Stem Cell Transplantation | 2 | 2017 | 1204 | 0.090 |
Why?
|
Rabbits | 1 | 2012 | 718 | 0.090 |
Why?
|
Cysts | 1 | 2012 | 101 | 0.090 |
Why?
|
Models, Biological | 1 | 2016 | 1468 | 0.090 |
Why?
|
Severe Combined Immunodeficiency | 1 | 2011 | 106 | 0.090 |
Why?
|
Nuclear Envelope | 1 | 2011 | 17 | 0.090 |
Why?
|
Europe | 1 | 2012 | 357 | 0.090 |
Why?
|
Ultrasonography | 1 | 2015 | 941 | 0.090 |
Why?
|
Abdominal Neoplasms | 1 | 2011 | 33 | 0.090 |
Why?
|
Enzyme Induction | 1 | 2010 | 104 | 0.090 |
Why?
|
Neoplasm, Residual | 2 | 2009 | 122 | 0.090 |
Why?
|
Myofibroblasts | 1 | 2011 | 77 | 0.090 |
Why?
|
Signal Transduction | 4 | 2019 | 4585 | 0.090 |
Why?
|
Lung Neoplasms | 1 | 2020 | 1659 | 0.090 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2010 | 80 | 0.090 |
Why?
|
Transcriptome | 1 | 2016 | 973 | 0.080 |
Why?
|
Predictive Value of Tests | 1 | 2015 | 2178 | 0.080 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2011 | 212 | 0.080 |
Why?
|
Recurrence | 3 | 2025 | 1420 | 0.080 |
Why?
|
Transcription Factor HES-1 | 1 | 2009 | 19 | 0.080 |
Why?
|
Hepatocyte Nuclear Factor 4 | 1 | 2009 | 19 | 0.080 |
Why?
|
Insulin-Like Growth Factor II | 1 | 2009 | 41 | 0.080 |
Why?
|
Myogenin | 1 | 2008 | 10 | 0.080 |
Why?
|
Periodic Acid-Schiff Reaction | 1 | 2008 | 3 | 0.080 |
Why?
|
Severity of Illness Index | 1 | 2017 | 2918 | 0.080 |
Why?
|
Glycogen | 1 | 2008 | 63 | 0.070 |
Why?
|
Mice, Nude | 3 | 2020 | 717 | 0.070 |
Why?
|
Immunocompetence | 1 | 2008 | 33 | 0.070 |
Why?
|
Proto-Oncogene Proteins c-myc | 2 | 2020 | 201 | 0.070 |
Why?
|
Piperazines | 1 | 2010 | 242 | 0.070 |
Why?
|
Molecular Targeted Therapy | 1 | 2010 | 373 | 0.070 |
Why?
|
Chromosomes, Human, Pair 9 | 1 | 2008 | 108 | 0.070 |
Why?
|
Rhabdomyosarcoma, Embryonal | 1 | 2008 | 51 | 0.070 |
Why?
|
Extremities | 1 | 2008 | 83 | 0.070 |
Why?
|
Remission Induction | 2 | 2019 | 300 | 0.070 |
Why?
|
Membrane Proteins | 2 | 2020 | 1533 | 0.070 |
Why?
|
ErbB Receptors | 1 | 2009 | 284 | 0.070 |
Why?
|
Histological Techniques | 1 | 2007 | 22 | 0.070 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2009 | 284 | 0.070 |
Why?
|
Antineoplastic Agents | 3 | 2019 | 1705 | 0.070 |
Why?
|
Neoplastic Stem Cells | 1 | 2009 | 318 | 0.070 |
Why?
|
Lymphoma, Non-Hodgkin | 2 | 2005 | 164 | 0.070 |
Why?
|
Skin | 1 | 2010 | 519 | 0.070 |
Why?
|
Pyrimidines | 1 | 2010 | 375 | 0.070 |
Why?
|
Syndrome | 1 | 2009 | 1121 | 0.070 |
Why?
|
Uterine Neoplasms | 1 | 2008 | 104 | 0.070 |
Why?
|
DNA Methylation | 1 | 2013 | 1041 | 0.070 |
Why?
|
Antibodies, Monoclonal | 1 | 2012 | 1033 | 0.060 |
Why?
|
Pediatrics | 3 | 2024 | 1157 | 0.060 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2009 | 393 | 0.060 |
Why?
|
Lymphoproliferative Disorders | 2 | 1998 | 225 | 0.060 |
Why?
|
Disease Progression | 3 | 2021 | 2089 | 0.060 |
Why?
|
Immunoglobulin lambda-Chains | 1 | 2006 | 11 | 0.060 |
Why?
|
Poliovirus Vaccine, Inactivated | 1 | 2005 | 12 | 0.060 |
Why?
|
Immunoglobulin kappa-Chains | 1 | 2006 | 30 | 0.060 |
Why?
|
Survival Analysis | 3 | 2016 | 1520 | 0.060 |
Why?
|
Genotype | 1 | 2012 | 2568 | 0.060 |
Why?
|
Hashimoto Disease | 1 | 2006 | 22 | 0.060 |
Why?
|
Homeodomain Proteins | 1 | 2009 | 555 | 0.060 |
Why?
|
Ribonucleoproteins | 2 | 1996 | 64 | 0.060 |
Why?
|
Hematopoietic Stem Cells | 1 | 2009 | 543 | 0.060 |
Why?
|
Nuclear Proteins | 3 | 2018 | 1273 | 0.060 |
Why?
|
Receptors, Purinergic P2Y | 1 | 2025 | 6 | 0.060 |
Why?
|
Aged, 80 and over | 3 | 2011 | 6607 | 0.060 |
Why?
|
Age of Onset | 2 | 2020 | 601 | 0.060 |
Why?
|
Cell Proliferation | 3 | 2020 | 2356 | 0.060 |
Why?
|
Chromosomes, Human, Pair 21 | 2 | 1996 | 40 | 0.060 |
Why?
|
Receptors, Cytokine | 1 | 2025 | 68 | 0.060 |
Why?
|
Prospective Studies | 3 | 2021 | 6171 | 0.060 |
Why?
|
Reproducibility of Results | 1 | 2011 | 2899 | 0.060 |
Why?
|
Apoptosis | 2 | 2022 | 1810 | 0.060 |
Why?
|
Cost Savings | 1 | 2024 | 71 | 0.060 |
Why?
|
Liquid Biopsy | 1 | 2024 | 14 | 0.060 |
Why?
|
Pathology, Molecular | 1 | 2024 | 59 | 0.060 |
Why?
|
Lymphoma | 2 | 2005 | 323 | 0.060 |
Why?
|
Breast Neoplasms | 1 | 2016 | 2518 | 0.060 |
Why?
|
Fibrous Dysplasia of Bone | 1 | 2003 | 7 | 0.060 |
Why?
|
Melanoma | 2 | 2006 | 944 | 0.060 |
Why?
|
Coloring Agents | 1 | 2024 | 77 | 0.060 |
Why?
|
Fibrous Dysplasia, Polyostotic | 1 | 2003 | 7 | 0.050 |
Why?
|
Risk Assessment | 3 | 2021 | 3470 | 0.050 |
Why?
|
Myxoma | 1 | 2003 | 29 | 0.050 |
Why?
|
Tertiary Care Centers | 1 | 2024 | 239 | 0.050 |
Why?
|
Chromosomes, Human, Pair 14 | 1 | 2024 | 102 | 0.050 |
Why?
|
Inflammation | 1 | 2011 | 1447 | 0.050 |
Why?
|
Prevalence | 1 | 2010 | 2467 | 0.050 |
Why?
|
Anemia, Iron-Deficiency | 1 | 2006 | 136 | 0.050 |
Why?
|
Carcinogens | 1 | 2023 | 152 | 0.050 |
Why?
|
Cell Adhesion Molecules, Neuronal | 1 | 2003 | 78 | 0.050 |
Why?
|
Margins of Excision | 1 | 2023 | 51 | 0.050 |
Why?
|
B-Lymphocytes | 1 | 2006 | 534 | 0.050 |
Why?
|
HSP40 Heat-Shock Proteins | 1 | 2022 | 22 | 0.050 |
Why?
|
Interleukin-6 | 1 | 2024 | 420 | 0.050 |
Why?
|
Extracellular Matrix Proteins | 1 | 2003 | 157 | 0.050 |
Why?
|
Historiography | 1 | 2002 | 2 | 0.050 |
Why?
|
State Medicine | 1 | 2002 | 12 | 0.050 |
Why?
|
World Health Organization | 1 | 2022 | 107 | 0.050 |
Why?
|
E2F6 Transcription Factor | 1 | 2001 | 1 | 0.050 |
Why?
|
Activin Receptors | 1 | 2001 | 14 | 0.050 |
Why?
|
Fourth Ventricle | 1 | 2021 | 10 | 0.050 |
Why?
|
Biomarkers | 1 | 2010 | 3095 | 0.050 |
Why?
|
B7-H1 Antigen | 1 | 2022 | 120 | 0.050 |
Why?
|
Programmed Cell Death 1 Receptor | 1 | 2022 | 128 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 3 | 2008 | 1075 | 0.050 |
Why?
|
Clinical Laboratory Techniques | 1 | 2022 | 140 | 0.040 |
Why?
|
Cell Line | 2 | 2016 | 2760 | 0.040 |
Why?
|
Ligands | 1 | 2022 | 539 | 0.040 |
Why?
|
Brain Stem | 1 | 2021 | 116 | 0.040 |
Why?
|
Inpatients | 1 | 2024 | 500 | 0.040 |
Why?
|
Nucleotidyltransferases | 1 | 2020 | 43 | 0.040 |
Why?
|
Cell Cycle | 2 | 2015 | 619 | 0.040 |
Why?
|
Cerebral Cortex | 1 | 2003 | 455 | 0.040 |
Why?
|
Hospitals, Pediatric | 1 | 2024 | 766 | 0.040 |
Why?
|
Nerve Tissue Proteins | 2 | 2003 | 1126 | 0.040 |
Why?
|
Transplantation, Heterologous | 2 | 1997 | 260 | 0.040 |
Why?
|
Frozen Sections | 1 | 1999 | 25 | 0.040 |
Why?
|
Heterogeneous-Nuclear Ribonucleoproteins | 2 | 1996 | 24 | 0.040 |
Why?
|
Chromatin | 1 | 2022 | 568 | 0.040 |
Why?
|
Proteasome Inhibitors | 1 | 2019 | 60 | 0.040 |
Why?
|
Mice, 129 Strain | 1 | 2019 | 98 | 0.040 |
Why?
|
Unfolded Protein Response | 1 | 2019 | 62 | 0.040 |
Why?
|
Hypercalcemia | 1 | 2018 | 39 | 0.040 |
Why?
|
Receptor, ErbB-2 | 1 | 2022 | 516 | 0.040 |
Why?
|
Granulosa Cell Tumor | 1 | 2018 | 39 | 0.040 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2019 | 103 | 0.040 |
Why?
|
Practice Patterns, Physicians' | 1 | 2024 | 735 | 0.040 |
Why?
|
Loss of Heterozygosity | 1 | 2018 | 129 | 0.040 |
Why?
|
Recombinant Fusion Proteins | 3 | 1996 | 772 | 0.040 |
Why?
|
Proto-Oncogenes | 1 | 1997 | 34 | 0.040 |
Why?
|
Genes, Retinoblastoma | 1 | 1997 | 18 | 0.040 |
Why?
|
Codon, Nonsense | 1 | 2018 | 131 | 0.040 |
Why?
|
Tissue Donors | 2 | 1998 | 494 | 0.030 |
Why?
|
DNA Helicases | 1 | 2018 | 235 | 0.030 |
Why?
|
Genes, p53 | 1 | 1997 | 215 | 0.030 |
Why?
|
Drug Therapy | 1 | 2017 | 88 | 0.030 |
Why?
|
Molecular Motor Proteins | 1 | 2016 | 29 | 0.030 |
Why?
|
International Agencies | 1 | 2016 | 29 | 0.030 |
Why?
|
Gene Expression | 2 | 2005 | 1561 | 0.030 |
Why?
|
Myosin Heavy Chains | 1 | 2016 | 77 | 0.030 |
Why?
|
United States | 1 | 2012 | 10942 | 0.030 |
Why?
|
Japan | 1 | 2016 | 133 | 0.030 |
Why?
|
Heterozygote | 1 | 2018 | 672 | 0.030 |
Why?
|
Delivery of Health Care | 1 | 2002 | 616 | 0.030 |
Why?
|
Chromosome Deletion | 1 | 2019 | 651 | 0.030 |
Why?
|
Germinal Center | 2 | 2006 | 38 | 0.030 |
Why?
|
Ovary | 1 | 2018 | 380 | 0.030 |
Why?
|
Nasal Mucosa | 1 | 1996 | 66 | 0.030 |
Why?
|
Bone Marrow Transplantation | 1 | 1998 | 575 | 0.030 |
Why?
|
Genome, Human | 1 | 2022 | 1284 | 0.030 |
Why?
|
Stem Cell Transplantation | 1 | 2017 | 239 | 0.030 |
Why?
|
Wnt Signaling Pathway | 1 | 2016 | 193 | 0.030 |
Why?
|
Up-Regulation | 2 | 2009 | 871 | 0.030 |
Why?
|
Tamoxifen | 1 | 2016 | 363 | 0.030 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2016 | 257 | 0.030 |
Why?
|
Adenosine Triphosphate | 1 | 2015 | 282 | 0.030 |
Why?
|
Proportional Hazards Models | 2 | 2008 | 1365 | 0.030 |
Why?
|
Surveys and Questionnaires | 1 | 2024 | 3745 | 0.030 |
Why?
|
RNA, Small Interfering | 1 | 2016 | 667 | 0.030 |
Why?
|
Antigens, Surface | 1 | 2014 | 117 | 0.030 |
Why?
|
DNA, Viral | 2 | 2005 | 480 | 0.030 |
Why?
|
Los Angeles | 1 | 2013 | 16 | 0.030 |
Why?
|
Immediate-Early Proteins | 1 | 1994 | 58 | 0.030 |
Why?
|
Disseminated Intravascular Coagulation | 1 | 2014 | 68 | 0.030 |
Why?
|
Axilla | 1 | 2013 | 39 | 0.030 |
Why?
|
MutS Homolog 2 Protein | 1 | 2013 | 39 | 0.030 |
Why?
|
MutL Protein Homolog 1 | 1 | 2013 | 53 | 0.030 |
Why?
|
Blotting, Western | 1 | 2015 | 1108 | 0.030 |
Why?
|
S100 Proteins | 1 | 2013 | 46 | 0.030 |
Why?
|
Neurons | 1 | 2003 | 1940 | 0.030 |
Why?
|
Sequence Deletion | 1 | 2015 | 527 | 0.030 |
Why?
|
Chromosomes, Human, Pair 15 | 1 | 2014 | 160 | 0.030 |
Why?
|
Incidence | 1 | 2020 | 3155 | 0.020 |
Why?
|
Anemia, Myelophthisic | 1 | 2012 | 2 | 0.020 |
Why?
|
Gene Expression Profiling | 2 | 2010 | 1751 | 0.020 |
Why?
|
Bone Marrow Examination | 1 | 2012 | 14 | 0.020 |
Why?
|
Reticulin | 1 | 2012 | 8 | 0.020 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2016 | 733 | 0.020 |
Why?
|
Clone Cells | 2 | 2006 | 168 | 0.020 |
Why?
|
DNA Repair-Deficiency Disorders | 1 | 2011 | 4 | 0.020 |
Why?
|
Remission, Spontaneous | 1 | 2012 | 69 | 0.020 |
Why?
|
Receptors, Thrombopoietin | 1 | 2012 | 31 | 0.020 |
Why?
|
RNA, Messenger | 3 | 2007 | 2824 | 0.020 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2015 | 1026 | 0.020 |
Why?
|
Splenomegaly | 1 | 2012 | 33 | 0.020 |
Why?
|
Hepatitis C | 1 | 2015 | 367 | 0.020 |
Why?
|
Adenosine Deaminase | 1 | 2011 | 89 | 0.020 |
Why?
|
Staining and Labeling | 1 | 2012 | 187 | 0.020 |
Why?
|
Antigens, CD | 1 | 2013 | 432 | 0.020 |
Why?
|
Janus Kinase 2 | 1 | 2012 | 131 | 0.020 |
Why?
|
Eosinophilia | 1 | 2012 | 101 | 0.020 |
Why?
|
Collagen | 1 | 2012 | 320 | 0.020 |
Why?
|
Early Termination of Clinical Trials | 1 | 2010 | 16 | 0.020 |
Why?
|
Imatinib Mesylate | 1 | 2010 | 46 | 0.020 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2010 | 73 | 0.020 |
Why?
|
Adipose Tissue | 1 | 2013 | 465 | 0.020 |
Why?
|
Mice, Inbred C57BL | 1 | 2019 | 4416 | 0.020 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2011 | 259 | 0.020 |
Why?
|
Benzamides | 1 | 2010 | 109 | 0.020 |
Why?
|
Terminology as Topic | 1 | 2011 | 223 | 0.020 |
Why?
|
PAX7 Transcription Factor | 1 | 2008 | 17 | 0.020 |
Why?
|
MyoD Protein | 1 | 2008 | 23 | 0.020 |
Why?
|
Hyaluronan Receptors | 1 | 2008 | 66 | 0.020 |
Why?
|
Case-Control Studies | 2 | 2005 | 3312 | 0.020 |
Why?
|
Epigenesis, Genetic | 1 | 2013 | 697 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2010 | 729 | 0.020 |
Why?
|
Vulva | 1 | 2008 | 16 | 0.020 |
Why?
|
Early Detection of Cancer | 1 | 2011 | 362 | 0.020 |
Why?
|
Mutation, Missense | 1 | 2012 | 878 | 0.020 |
Why?
|
Receptors, Notch | 1 | 2009 | 205 | 0.020 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2007 | 81 | 0.020 |
Why?
|
Regression Analysis | 1 | 2008 | 781 | 0.020 |
Why?
|
Gene Expression Regulation | 1 | 1995 | 2526 | 0.020 |
Why?
|
Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 2006 | 4 | 0.020 |
Why?
|
Protein Kinase C | 1 | 2007 | 149 | 0.020 |
Why?
|
Neprilysin | 1 | 2006 | 19 | 0.020 |
Why?
|
Pseudolymphoma | 1 | 2005 | 4 | 0.020 |
Why?
|
Costa Rica | 1 | 2005 | 14 | 0.020 |
Why?
|
HIV Seronegativity | 1 | 2005 | 26 | 0.020 |
Why?
|
Drug Contamination | 1 | 2005 | 37 | 0.020 |
Why?
|
Genes, Viral | 1 | 2005 | 185 | 0.020 |
Why?
|
Thyroid Gland | 1 | 2006 | 104 | 0.010 |
Why?
|
Postoperative Complications | 2 | 2012 | 3080 | 0.010 |
Why?
|
Lymphoma, B-Cell | 1 | 2005 | 141 | 0.010 |
Why?
|
LDL-Receptor Related Proteins | 1 | 2003 | 9 | 0.010 |
Why?
|
Receptors, Lipoprotein | 1 | 2003 | 11 | 0.010 |
Why?
|
Mice, Neurologic Mutants | 1 | 2003 | 74 | 0.010 |
Why?
|
Flow Cytometry | 1 | 2006 | 801 | 0.010 |
Why?
|
Trisomy | 1 | 2003 | 102 | 0.010 |
Why?
|
Nucleic Acid Hybridization | 1 | 2003 | 396 | 0.010 |
Why?
|
Receptors, LDL | 1 | 2003 | 88 | 0.010 |
Why?
|
History, 16th Century | 1 | 2002 | 27 | 0.010 |
Why?
|
History, 17th Century | 1 | 2002 | 35 | 0.010 |
Why?
|
Spain | 1 | 2002 | 60 | 0.010 |
Why?
|
History, 18th Century | 1 | 2002 | 70 | 0.010 |
Why?
|
HIV-1 | 1 | 2005 | 465 | 0.010 |
Why?
|
Comorbidity | 1 | 2005 | 1537 | 0.010 |
Why?
|
Scalp | 1 | 2000 | 57 | 0.010 |
Why?
|
Prednisone | 1 | 2000 | 277 | 0.010 |
Why?
|
Vincristine | 1 | 2000 | 193 | 0.010 |
Why?
|
Fetus | 1 | 2003 | 587 | 0.010 |
Why?
|
Doxorubicin | 1 | 2000 | 290 | 0.010 |
Why?
|
Transcription, Genetic | 2 | 1995 | 1705 | 0.010 |
Why?
|
Y Chromosome | 1 | 1998 | 47 | 0.010 |
Why?
|
Cyclophosphamide | 1 | 2000 | 418 | 0.010 |
Why?
|
Viral Matrix Proteins | 1 | 1998 | 109 | 0.010 |
Why?
|
Phosphopyruvate Hydratase | 1 | 1998 | 31 | 0.010 |
Why?
|
Forearm | 1 | 1998 | 45 | 0.010 |
Why?
|
Polymorphism, Single-Stranded Conformational | 1 | 1997 | 70 | 0.010 |
Why?
|
Immunoenzyme Techniques | 1 | 1998 | 258 | 0.010 |
Why?
|
Sex Chromosomes | 1 | 1997 | 34 | 0.010 |
Why?
|
X Chromosome | 1 | 1998 | 338 | 0.010 |
Why?
|
Fragile X Mental Retardation Protein | 1 | 1998 | 124 | 0.010 |
Why?
|
Liver Failure | 1 | 1997 | 89 | 0.010 |
Why?
|
In Situ Hybridization | 1 | 1997 | 471 | 0.010 |
Why?
|
Kidney | 1 | 2003 | 1369 | 0.010 |
Why?
|
RNA, Viral | 1 | 1998 | 538 | 0.010 |
Why?
|
Activating Transcription Factor 1 | 1 | 1995 | 4 | 0.010 |
Why?
|
Transplantation, Homologous | 1 | 1997 | 667 | 0.010 |
Why?
|
Mice, Inbred BALB C | 1 | 1997 | 1000 | 0.010 |
Why?
|
Oligodeoxyribonucleotides | 1 | 1995 | 135 | 0.010 |
Why?
|
Retroviridae Proteins, Oncogenic | 1 | 1994 | 12 | 0.010 |
Why?
|
Precipitin Tests | 1 | 1994 | 155 | 0.010 |
Why?
|
Reoperation | 1 | 1997 | 834 | 0.010 |
Why?
|
Early Growth Response Protein 1 | 1 | 1994 | 37 | 0.010 |
Why?
|
In Vitro Techniques | 1 | 1995 | 983 | 0.010 |
Why?
|
Chromosome Disorders | 1 | 1995 | 311 | 0.010 |
Why?
|
Cloning, Molecular | 1 | 1994 | 897 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 1995 | 1410 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 1994 | 2714 | 0.010 |
Why?
|
HIV Infections | 1 | 2000 | 1899 | 0.000 |
Why?
|